FDA-Approved drug shows promise for Tough-to-Treat EoE with strictures
NCT ID NCT06352073
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well dupilumab, an already approved drug, works for people with severe eosinophilic esophagitis (EoE) that has caused narrowing of the esophagus. About 23 participants aged 16 and older will receive weekly injections of dupilumab for one year. The goal is to see if the drug can reduce inflammation and improve swallowing, potentially reducing the need for dilation procedures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Swallowable sponge could replace endoscopy for esophagitis monitoring
- Blood tests may replace scopes for EoE diagnosis
- Massive new registry aims to crack the code on mysterious gut disorders
- 300 kids with EoE enrolled in landmark database study
- Could ditching milk soothe a painful esophagus? new trial tests Diet-Only approach
- Can cutting four foods ease Kids' esophagus inflammation?